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Introduction {#sec005}
============

The impact of chronic hepatitis C (CHC) infection on health-related quality of life (HRQoL) has received increasing interest over the past ten years \[[@pone.0215596.ref001],[@pone.0215596.ref002]\]. HRQoL has been especially shown to be impaired in patients with CHC \[[@pone.0215596.ref003]--[@pone.0215596.ref006]\]. With the advent of highly effective, and well tolerated, new direct-acting antivirals (DAAs), clinicians and patients emphasize that all those with HCV should receive these new treatments, not only to decrease HCV morbidity and mortality and/or HCV transmission, but also to improve patients\' HRQoL. Indeed, higher HRQoL has been found after a sustained virological response \[[@pone.0215596.ref007],[@pone.0215596.ref008]\]. The hypothesis is that, because of the impact of these treatments on HRQoL, and despite their high costs, they could be cost-effective even in those patients who are at the early stages of the disease. However, few studies have measured HRQoL \[[@pone.0215596.ref007],[@pone.0215596.ref009],[@pone.0215596.ref010]\].

HRQoL may be affected in a subgroup of HCV-infected patients although not all of them. A recent study conducted in France, the UK, and Germany generated a utility value set for CHC patients, stratified by stage of liver disease \[[@pone.0215596.ref008]\]. Patient characteristics such as male gender \[[@pone.0215596.ref011],[@pone.0215596.ref012]\], being unemployed, being an intravenous drug user, comorbidities, a liver disease stage above F2 \[[@pone.0215596.ref004],[@pone.0215596.ref013]--[@pone.0215596.ref015]\], genotype 3, and not having achieved sustained virological response (SVR), decreased HRQoL. Associations were also found between HRQoL and knowledge of diagnosis \[[@pone.0215596.ref016],[@pone.0215596.ref017]\] and or being naïve to treatment or not (in relation to adverse events of previous treatment) \[[@pone.0215596.ref018]--[@pone.0215596.ref020]\].

Beyond the level of disease severity, HRQoL for CHC patients may be impaired by the difficulty of accepting the disease and its social impacts. These non-clinical aspects had not been widely assessed. The availability of new DAAs may change not only the HRQoL of CHC patients, but also their perception of the disease.

The objective of the present study was to evaluate the HRQoL and their determinants in untreated patients with CHC, before the initiation of new DAAs in France, in a period during which patients were aware of DAAs availability.

Methods {#sec006}
=======

Study design and participants {#sec007}
-----------------------------

The French ethics committee, Commission nationale de l\'informatique et des libertés de France (CNIL) approved by written the study (N/Ref.: MMS/FLR/AR146546). A cross-sectional study was conducted between January 2014 and January 2015 in three reference centers (Paris, Lille and Montpellier). Patients with CHC were eligible for this study if they were 18--70 years old, had not received a liver transplant, and were not receiving treatment for CHC. All patients meeting the inclusion criteria were invited by their physician to participate. The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details.

All participants completed a questionnaire administered face to face by a clinical research fellow, except at Lille, where it was self-administered. The questionnaire proposed 50 questions including measures of HRQoL and patients' characteristics: comorbidities, circumstances of HCV discovery, CHC clinical history and its evolution, information and perception of CHC (using four-point Likert scales \[[@pone.0215596.ref021]\]), impact of CHC on daily life including dependence on alcohol (according to a CAGE (Cut-down, Annoyed, Guilty, Eye-opener) questionnaire \[[@pone.0215596.ref022]\]), and positioning in relation to HCV treatments. Fibrosis stage and genotype were obtained from medical records.

Measure of quality of life {#sec008}
--------------------------

HRQoL was assessed using EQ-5D, for which a time trade-off (TTO) French utility value set is available \[[@pone.0215596.ref023]\]. This questionnaire contains five generic questions on mobility, self-care, habitual activities, pain/discomfort and anxiety/depression that were declined on three levels (EQ-5D-3L): no problems, some problems, and extreme problems.

HRQoL was also evaluated through two visual analogue scales (VAS), a vertical line of 100 mm: one assessing overall health \[[@pone.0215596.ref024]\] defined between 0 (worst) and 100 (best imaginable health), and one assessing overall fatigue \[[@pone.0215596.ref025]\] defined between 0 (none) and 100 (worst fatigue). The patient placed a mark between these two extremities according to his overall health and his level of fatigue felt the day of the interview.

Statistical analysis {#sec009}
--------------------

Chi-square tests were used to compare patients' characteristics according to their stage of fibrosis (F0-F1, F2 and F3-F4). HRQoL was evaluated through the estimation of mean EQ5D utility index \[[@pone.0215596.ref023]\], and mean VAS values on general health \[[@pone.0215596.ref024]\] and fatigue \[[@pone.0215596.ref025]\]. Determinants of the EQ-5D utility index, overall health, and overall fatigue, were analyzed with mixed models taking into account the cluster effect (hepatology centers and physicians). Variables associated with the outcome in the univariate analysis (p\<0.20) were introduced in the multivariate analysis. To avoid the inclusion of highly correlated variables in the multivariate analysis, we performed a principal component analysis on all 12 subjective Likert scales on knowledge, attitude, belief, and perception. Accordingly, four variables added little information and were removed: perceived future progression of CHC, severity of CHC disease, knowledge about the availability of new treatments, and knowledge about the chances of healing using older treatments. Next, a step-by-step backward elimination procedure with a significance threshold of 0.05 was used to identify the variables independently associated with each outcome studied, while four socio-demographic variables (gender, age, place of birth, education) were forced in all multivariate models. Data were analyzed using SAS version 9.4.

Results {#sec010}
=======

Demographic characteristics and clinical data {#sec011}
---------------------------------------------

A total of 505 HCV-mono-infected patients were enrolled in the study ([Table 1](#pone.0215596.t001){ref-type="table"}); 481 had complete records. The detailed socio-demographic and clinical characteristics of patients are presented according to fibrosis stage. Forty-one percent of patients had minimal fibrosis (F0-F1), whereas 35% were at an advanced stage F3-F4. Overall, 52% were men; the majority of patients were over 50 years old (72%), born in France (74%), had a bachelor\'s degree level of education (54%), were in employment (55%), and had children (75%). The distribution of gender, age, education and parenthood varied according to fibrosis stage. In particular, women represented 58% of F0-F1, 46% of F2 and 36% of F3-F4 (*p*\<0.0001).

10.1371/journal.pone.0215596.t001

###### Patient characteristics, n (%).

![](pone.0215596.t001){#pone.0215596.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                 Class                          Total        F0-F1        F2           F3-F4        *P* value
  ---------------------------------------------------------------------------------------- ------------------------------ ------------ ------------ ------------ ------------ -----------
  Gender                                                                                   Male                           252 (52.4)   81 (41.5)    62 (53.5)    109 (64.1)   \< .0001

                                                                                           Female                         229 (47.6)   114 (58.5)   54 (46.5)    61 (35.9)    

  Age                                                                                      18--49                         133 (27.7)   75 (38.5)    22 (19.0)    36 (21.2)    0.006

                                                                                           50--54                         102 (21.2)   36 (18.5)    25 (21.6)    41 (24.1)    

                                                                                           55--59                         104 (21.6)   39 (20.0)    26 (22.4)    39 (22.9)    

                                                                                           60--64                         76 (15.8)    23 (11.8)    22 (19.0)    31 (18.2)    

                                                                                           65--70                         66 (13.7)    22 (11.3)    21 (18.1)    23 (13.5)    

  Place of birth                                                                           France                         354 (73.6)   136 (69.7)   88 (75.9)    130 (76.5)   0.284

                                                                                           Abroad                         127 (26.4)   59 (30.3)    28 (24.1)    40 (23.5)    

  Education                                                                                No bachelor level              223 (46.4)   75 (38.5)    58 (50.0)    90 (52.9)    0.015

                                                                                           Bachelor level                 258 (53.6)   120 (61.5)   58 (50.0)    80 (47.1)    

  Work                                                                                     Yes                            263 (54.7)   111 (56.9)   69 (59.5)    83 (48.8)    0.148

                                                                                           No                             218 (45.3)   84 (43.1)    47 (40.5)    87 (51.2)    

  Children                                                                                 Yes                            361 (75.1)   134 (68.7)   96 (82.8)    131 (77.1)   0.016

                                                                                           No                             120 (24.9)   61 (31.3)    20 (17.2)    39 (22.9)    

  Centers                                                                                  Paris Cochin                   221 (45.9)   104 (53.3)   52 (44.8)    65 (38.2)    0.001

                                                                                           Lille                          112 (23.3)   52 (26.7)    26 (22.4)    34 (20.0)    

                                                                                           Montpellier                    148 (30.8)   39 (20.0)    38 (32.8)    71 (41.8)    

  Physician                                                                                A                              28 (5.8)     19 (9.7)     2 (1.7)      7 (4.1)      \< .0001

                                                                                           B                              72 (14.9)    31 (15.9)    22 (19.0)    19 (11.2)    

                                                                                           C                              12 (2.5)     2 (1.0)      2 (1.7)      8 (4.7)      

                                                                                           D                              17 (3.5)     7 (3.6)      5 (4.3)      5 (2.9)      

                                                                                           E                              24 (4.9)     15 (7.7)     1 (0.9)      8 (4.7)      

                                                                                           F                              121 (25.2)   54 (27.7)    37 (31.9)    30 (17.7)    

                                                                                           G                              45 (9.4)     21 (10.8)    8 (6.9)      16 (9.4)     

                                                                                           H                              14 (2.9)     7 (3.6)      1 (0.9)      6 (3.5)      

                                                                                           I                              148 (30.8)   39 (20.0)    38 (32.8)    71 (41.8)    

  Screening context                                                                        Health check-up                259 (54.1)   107 (54.9)   61 (52.6)    91 (54.2)    0.271

                                                                                           Medical follow-up              40 (8.4)     19 (9.7)     12 (10.3)    9 (5.4)      

                                                                                           Blood donation                 106 (22.1)   46 (23.6)    26 (22.4)    34 (20.2)    

                                                                                           Persistent fatigue             74 (15.6)    23 (11.8)    17 (14.7)    34 (20.2)    

  Genotype                                                                                 1                              311 (64.7)   127 (65.1)   82 (70.7)    102 (60.0)   0.416

                                                                                           2.3                            94 (19.5)    39 (20.0)    17 (14.7)    38 (22.4)    

                                                                                           4.5.6                          76 (15.8)    29 (14.9)    17 (14.7)    30 (17.7)    

  Treatment history                                                                        Naïve                          240 (49.9)   131 (67.2)   51 (44.0)    58 (34.1)    \< .0001

                                                                                           Non-naïve                      241 (50.1)   64 (32.8)    65 (56.0)    112 (65.9)   

  Severe comorbidities[^a^](#t001fn002){ref-type="table-fn"}                               Yes                            180 (37.4)   67 (34.4)    42 (36.2)    71 (41.8)    0.329

                                                                                           No                             301 (62.6)   128 (65.6)   74 (63.8)    99 (58.2)    

  Overweight[^b^](#t001fn003){ref-type="table-fn"}                                         Yes                            200 (41.6)   66 (33.9)    57 (49.1)    77 (45.3)    0.014

                                                                                           No                             281 (58.4)   129 (66.1)   59 (50.9)    93 (54.7)    

  Psychiatric disorders                                                                    Yes                            53 (11.0)    16 (8.2)     14 (12.1)    23 (13.5)    0.247

                                                                                           No                             428 (89.0)   179 (91.8)   102 (88)     147 (86.5)   

  Injection or nasal drug use                                                              Yes                            201 (41.8)   64 (32.8)    50 (43.1)    87 (51.2)    0.002

  No                                                                                       280 (58.2)                     131 (67.2)   66 (56.9)    83 (48.8)                 

  Alcohol Use Disorders[^c^](#t001fn004){ref-type="table-fn"}                              Yes                            152 (31.6)   41 (21.0)    28 (24.1)    83 (48.8)    \< .0001

  No                                                                                       329 (68.4)                     154 (79.0)   88 (75.9)    87 (51.2)                 

  Perceived progression of CHC between infection and today                                 Very comforting                56 (12.2)    37 (20.2)    10 (8.9)     9 (5.6)      \< .0001

  Rather comforting                                                                        250 (54.6)                     115 (62.8)   75 (66.4)    60 (37.0)                 

  Rather worrying                                                                          112 (24.3)                     23 (12.6)    22 (19.5)    67 (41.4)                 

  Very worrying                                                                            40 (8.7)                       8 (4.4)      6 (5.3)      26 (16.1)                 

  Perceived future progression of CHC\                                                     Very comforting                96 (20.1)    51 (26.4)    21 (18.3)    24 (14.1)    0.081

  Rather comforting                                                                        158 (33.1)                     62 (32.1)    39 (33.9)    57 (33.5)                 

  Rather worrying                                                                          164 (34.3)                     56 (29.0)    44 (38.3)    64 (37.7)                 

  Very worrying                                                                            60 (12.6)                      24 (12.5)    11 (9.6)     25 (14.7)                 

  Level of information[^d^](#t001fn005){ref-type="table-fn"}                               Informed                       407 (85.2)   166 (85.6)   96 (83.5)    145 (85.8)   0.845

                                                                                           Uninformed                     71 (14.9)    28 (14.4)    19 (16.5)    24 (14.2)    

  Personal research on CHC[^e^](#t001fn006){ref-type="table-fn"}                           Yes                            338 (70.3)   142 (72.8)   84 (72.4)    112 (65.9)   0.297

  No                                                                                       143 (29.7)                     53 (27.2)    32 (27.6)    58 (34.1)                 

  Severity of CHC disease[^f^](#t001fn007){ref-type="table-fn"}\                           Not serious                    32 (6.7)     17 (8.8)     11 (9.6)     4 (2.4)      0.020

  Rather serious                                                                           251 (52.6)                     104 (53.6)   64 (55.7)    83 (49.4)                 

  Very serious                                                                             194 (40.7)                     73 (37.6)    40 (34.8)    81 (48.2)                 

  Knowledge of the availability of new treatments[^g^](#t001fn008){ref-type="table-fn"}    Very knowledgeable             103 (21.8)   46 (24.0)    31 (27.0)    26 (15.7)    0.119

  Fairly well informed                                                                     243 (51.4)                     93 (48.4)    53 (46.1)    97 (58.4)                 

  Uninformed                                                                               127 (26.8)                     53 (27.6)    31 (27.0)    43 (25.9)                 

  Knowledge of chances of healing with older treatments                                    Yes                            295 (62.1)   118 (61.1)   70 (61.4)    107 (63.7)   0.87

  No                                                                                       180 (37.9)                     75 (38.9)    44 (38.6)    61 (36.3)                 

  Knowledge of chances of healing with new treatments                                      Yes                            341 (71.9)   132 (69.1)   89 (77.4)    120 (71.4)   0.291

  No                                                                                       133 (28.1)                     59 (30.9)    26 (22.6)    48 (28.6)                 

  Living with CHC in society                                                               Difficult to live in society   261 (56.7)   109 (59.6)   66 (57.4)    86 (53.1)    0.474

  Easy to live in society                                                                  199 (43.3)                     74 (40.4)    49 (42.6)    76 (46.9)                 

  Need to talk with people with CHC\                                                       Very often                     9 (1.9)      3 (1.6)      2 (1.8)      4 (2.5)      0.722

  Often                                                                                    46 (9.9)                       21 (11.2)    10 (8.8)     15 (9.2)                  

  Occasionally                                                                             141 (30.4)                     53 (28.3)    31 (27.2)    57 (35.0)                 

  Not at all                                                                               268 (57.8)                     110 (58.8)   71 (62.3)    87 (53.4)                 

  Speak freely about CHC with friends                                                      Yes                            326 (68.3)   123 (64.1)   75 (65.2)    128 (75.3)   0.051

  No                                                                                       151 (31.7)                     69 (35.9)    40 (34.8)    42 (24.7)                 

  Entourage uncomfortable since their knowledge of the CHC                                 Yes, they are uncomfortable    73 (15.4)    24 (12.6)    19 (16.7)    30 (17.9)    0.032

  None is uncomfortable                                                                    307 (64.9)                     118 (61.8)   72 (63.2)    117 (69.6)                

  No, because nobody knows                                                                 93 (19.7)                      49 (25.7)    23 (20.2)    21 (12.5)                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N = 481 excluding genotype and stage of fibrosis unknown

^a^Diabetes, non-liver related transplant, psychiatric disorders, drug addiction / alcohol

^b^BMI\> 25 kg/m^2^

^c^Patients hospitalized for alcohol dependence or currently receiving substitution treatment

^d^\"Uninformed\" regroups \"rather uninformed\" and \"very badly informed\"

^e^Except the physician's information

^f^"Not serious" regroups \"Not serious at all\" and \"Rather not matter\"

^g^"Uninformed" regroups \"Rather uninformed\" and \"Very badly informed\"

Regarding the information about CHC, the majority of patients were in Paris (46%), had been screened for HCV through routine health check-ups (54%), and had a genotype-1 virus (65%). The distribution of centers and physicians, and the treatment history, varied according to fibrosis stage: the majority of F0-F1 and F2 patients were enrolled in Paris (53% and 45%, respectively), whereas the majority of F4 patients were enrolled in Montpellier (42%) (*p* = 0.001); 67% F0-F1 and 34% of F3-F4 were treatment-naïve (*p*\<0.0001).

Regarding diseases other than CHC, 37% of patients reported severe comorbidities, 42% were overweight (BMI\>25 kg/m^2^), and 11% had psychiatric disorders. Thirty-two percent of patients had alcohol dependence and 42% reported a personal history of injection or nasal drug use. The percentages of patients who were overweight, patients who engaged in drug use, and especially patients with alcohol dependence, increased with fibrosis stage: 21% of F0-F1 vs. 49% of F3-F4 had alcohol dependence (*p*\<0.0001).

Perception of the disease, level of information, and living with CHC {#sec012}
--------------------------------------------------------------------

For 67% of patients ([Table 1](#pone.0215596.t001){ref-type="table"}), the perceived progression of CHC between infection and the day of interview was very or rather comforting (83% among F0-F1 vs. 43% among F3-F4, *p*\<0.0001). When looking ahead to years to come, 53% perceived CHC progression as very or rather comforting (58% among F0-F1 vs. 48% among F3-F4, *p* = 0.08). By contrast, the disease was perceived as very serious in 41% of patients (38% among F0-F1 vs. 48% among F3-F4, *p* = 0.02). Regarding knowledge of treatments, 73% felt informed about the availability of new treatments, 62% reported having knowledge about the chances of recovery with older treatments (72% with regard to new treatments), without any difference according to stage of fibrosis.

For 57% of patients it was difficult to live with CHC in society. Thirty-two percent of patients said they spoke freely about their CHC disease with their friends (36% among the F0-F1 vs. 25% for F3-F4, *p* = 0.05). Finally, 15% of patients felt that their entourage had been uncomfortable since finding out about their CHC status (13% among the F0-F1 vs. 18% for F3-F4), whereas 20% reported that members of their entourage did not know about their CHC (26% for F0-F1 vs. 12% for F3-F4).

Estimation of utilities and their determinants {#sec013}
----------------------------------------------

The mean EQ-5D utility was 0.80, while mean VAS values were 68.8 for overall health and 44.7 for overall fatigue. In univariate analyses ([Table 2](#pone.0215596.t002){ref-type="table"}), mean EQ-5D utility decreased with: older age (≥0.80 before 65 years old vs. 0.72 at 65--70 years old); lower levels of education (0.85 in patients with bachelor level vs. 0.75 in those without); being unemployed (0.86 for those working vs. 0.73 for those not working); having children (0.84 in patients without children vs. 0.79 in those with children). Mean EQ-5D utility also varied according to reference center, according to physician, and according to screening context. It also decreased both as the stage of fibrosis advanced (0.83 in F0-F1 and 0.82 in F2 vs. 0.76 in F3-F4) and in the presence of other diseases.

10.1371/journal.pone.0215596.t002

###### Determinants of HRQoL: Univariate analysis.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                Class                          EQ-5D   *P* value   VAS Health   *P* value   VAS fatigue   *P* value
  --------------------------------------------------------------------------------------- ------------------------------ ------- ----------- ------------ ----------- ------------- -----------
  Gender                                                                                  Male                           0.81    0.197       69.0         0.947       42.9          0.226

                                                                                          Female                         0.79                68.8                     46.1          

  Age                                                                                     18--49                         0.81    0.028       68.2         0.747       44.8          0.717

                                                                                          50--54                         0.81                68.1                     47.2          

                                                                                          55--59                         0.84                69.3                     43.7          

                                                                                          60--64                         0.80                71.7                     41.2          

                                                                                          65--70                         0.72                67.4                     44.5          

  Place of birth                                                                          France                         0.80    0.922       70.2         0.019       45.2          0.339

                                                                                          Abroad                         0.80                65.0                     42.3          

  Education                                                                               No bachelor level              0.75    \< .0001    65.7         0.003       47.5          0.038

                                                                                          Bachelor level                 0.85                71.6                     42.0          

  Work                                                                                    Yes                            0.86    \< .0001    72.9         \< .0001    41.6          0.017

                                                                                          No                             0.73                64.0                     47.9          

  Children                                                                                Yes                            0.79    0.029       68.2         0.202       45.7          0.090

                                                                                          No                             0.84                71.2                     40.3          

  Centers                                                                                 Paris                          0.86    \< .0001    72.3         0.005       39.4          0.002

                                                                                          Lille                          0.75                65.4                     49.3          

                                                                                          Montpellier                    0.76                66.2                     48.6          

  Physician                                                                               A                              0.83    0.002       66.3         0.173       51.1          0.009

                                                                                          B                              0.73                65.4                     47.2          

                                                                                          C                              0.70                64.0                     58.5          

                                                                                          D                              0.86                70.0                     40.0          

                                                                                          E                              0.87                75.8                     30.0          

                                                                                          F                              0.86                72.1                     42.8          

                                                                                          G                              0.83                72.2                     35.5          

                                                                                          H                              0.91                72.4                     32.5          

                                                                                          I                              0.76                66.2                     48.6          

  Screening context                                                                       Health check-up                0.82    0.015       69.2         0.050       42.6          0.076

                                                                                          Medical follow-up              0.87                76.0                     39.2          

                                                                                          Blood donation                 0.75                68.4                     46.6          

                                                                                          Persistent fatigue             0.79                64.5                     51.0          

  Fibrosis stage                                                                          F0-F1                          0.83    0.019       73.3         0.002       42.0          0.316

                                                                                          F2                             0.82                66.4                     46.4          

                                                                                          F3-F4                          0.76                65.8                     45.9          

  Genotype                                                                                1                              0.81    0.576       70.0         0.227       44.2          0.961

                                                                                          2.3                            0.78                67.7                     44.9          

                                                                                          4.5.6                          0.80                65.6                     45.1          

  Treatment-naïve                                                                         Naïve                          0.81    0.299       70.3         0.153       41.6          0.029

                                                                                          Non-naïve                      0.79                67.5                     47.3          

  Severe comorbidities[^a^](#t002fn001){ref-type="table-fn"}                              Yes                            0.75    \< .0001    65.3         0.007       46.9          0.175

  No                                                                                      0.83                                   70.9                     43.1                      

  Overweight[^b^](#t002fn002){ref-type="table-fn"}                                        Yes                            0.77    0.007       68.0         0.432       47.8          0.039

                                                                                          No                             0.82                69.5                     42.2          

  Psychiatric disorders                                                                   Yes                            0.73    0.01        59.2         0.001       58.3          0.001

                                                                                          No                             0.81                70.1                     42.8          

  Injection or nasal drug use                                                             Yes                            0.82    0.173       68.3         0.623       45.9          0.354

  No                                                                                      0.79                                   69.3                     43.4                      

  Alcohol Use Disorders[^c^](#t002fn003){ref-type="table-fn"}                             Yes                            0.79    0.312       68.0         0.563       46.9          0.227

  No                                                                                      0.81                                   69.3                     43.4                      

  Perceived progression of CHC between infection and today                                Very comforting                0.88    \< .0001    80.2         \< .0001    31.3          \< .0001

  Rather comforting                                                                       0.84                                   71.9                     42.2                      

  Rather worrying                                                                         0.73                                   61.0                     54.3                      

  Very worrying                                                                           0.66                                   55.3                     51.1                      

  Perceived future progression of CHC                                                     Very comforting                0.87    \< .0001    76.3         \< .0001    33.5          \< .0001

  Rather comforting                                                                       0.83                                   71.1                     40.8                      

  Rather worrying                                                                         0.79                                   67.1                     47.9                      

  Very worrying                                                                           0.66                                   55.5                     63.4                      

  Level of information[^d^](#t002fn004){ref-type="table-fn"}                              Informed                       0.82    0.001       70.4         0.001       43.4          0.038

                                                                                          Uninformed                     0.72                59.8                     51.3          

  Personal research on CHC[^e^](#t002fn005){ref-type="table-fn"}                          Yes                            0.81    0.324       68.6         0.683       45.4          0.285

  No                                                                                      0.79                                   69.5                     42.3                      

  Severity of CHC disease[^f^](#t002fn006){ref-type="table-fn"}                           Not serious                    0.80    0.025       70.1         0.172       36.0          0.131

  Rather serious                                                                          0.83                                   70.5                     43.9                      

  Very serious                                                                            0.77                                   66.7                     46.7                      

  Knowledge of the availability of new treatments[^g^](#t002fn007){ref-type="table-fn"}   Very knowledgeable             0.81    0.008       72.9         \< .0001    42.4          0.066

  Fairly well informed                                                                    0.83                                   70.9                     42.8                      

  Uninformed                                                                              0.75                                   61.3                     49.7                      

  Knowledge of chances of healing with older treatments                                   Yes                            0.82    0.005       70.5         0.032       43.8          0.515

  No                                                                                      0.77                                   66.2                     45.6                      

  Knowledge of chances of healing with new treatments                                     Yes                            0.82    0.008       70.5         0.007       44.0          0.577

  No                                                                                      0.76                                   64.6                     45.7                      

  Living with CHC in society                                                              Difficult to live in society   0.77    0.005       64.8         0.003       51.0          \< .0001

  Easy to live in society                                                                 0.83                                   72.0                     39.6                      

  Need to talk with people with CHC                                                       Very often                     0.82    0.307       57.5         0.039       51.3          0.005

  Often                                                                                   0.78                                   67.3                     44.2                      

  Occasionally                                                                            0.78                                   65.9                     51.2                      

  Not at all                                                                              0.82                                   71.1                     40.8                      

  Speak freely about CHC with friends                                                     Yes                            0.80    0.506       69.7         0.201       44.2          0.758

  No                                                                                      0.81                                   67.0                     45.1                      

  Entourage uncomfortable since their knowledge of the CHC\                               Yes, they are\                 0.71    0.001       59.2         \< .0001    58.2          \< .0001
                                                                                          uncomfortable                                                                             

  Noone is uncomfortable                                                                  0.83                                   72.2                     41.2                      

  No, because nobody knows                                                                0.80                                   65.6                     44.4                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Diabetes, non-liver related transplant, psychiatric disorders, drug addiction / alcohol

^b^BMI\>25 kg/m^2^

^c^Patients hospitalized for alcohol dependence or currently receiving substitution treatment

^d^"Uninformed" groups together "rather uninformed" and "very badly informed"

^e^Except the physician's information

^f^"Not serious" groups together "not serious at all" and "mostly not serious"

^g^"Uninformed" groups together "rather uninformed" and "very badly informed"

Mean EQ-5D utility decreased along with worse perceptions of CHC progression between infection and the day of enrollment (from 0.88 when very reassuring to 0.66 when very worrying), and of future progression of CHC (from 0.87 when very reassuring to 0.66 when very worrying). Moreover, it also decreased both when patients were not informed about CHC (from 0.82 to 0.72), and with a worse perception of CHC disease (from 0.80 to 0.77). Mean EQ-5D utility also increased with the level of knowledge of the availability of new treatments (from 0.75 to 0.83) and of the chances of healing with new treatments (from 0.76 to 0.82); the utilities were higher when patients were informed. Finally, mean EQ-5D was lower when the perception of life in society with CHC was difficult (0.77 vs. 0.83 when easy), and also when the feeling of the entourage was uncomfortable (0.71 vs. 0.83 when no one was uncomfortable).

Regarding VAS, similar associations were found ([Table 2](#pone.0215596.t002){ref-type="table"}) except that age was not associated either with general health and fatigue, or with the severity of the CHC disease. Moreover, as general health and fatigue deteriorated, the need to talk with people with CHC increased.

Finally, genotype, drug use and alcohol dependence did not affect either mean EQ-5D utilities or mean VAS values for overall health and fatigue.

In multivariate analysis ([Table 3](#pone.0215596.t003){ref-type="table"}), after adjustment on socio-demographic variables (gender, age, place of birth, education) and cluster effects (center and physician), EQ-5D utility remained significantly associated with being unemployed (0.80 for patients working vs. 0.72 for those not working), with the presence of severe comorbidities (0.79 without vs. 0.72 with comorbidities), with being overweight (0.78 without vs. 0.73 with overweight), and with a CHC progression perceived as rather or very worrying (from 0.84 for patients feeling CHC progression was very reassuring, to 0.66 for patients feeling it was very worrying).

10.1371/journal.pone.0215596.t003

###### Determinants of HRQoL: Multivariate analysis.

![](pone.0215596.t003){#pone.0215596.t003g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                     Class                         EQ5D (N = 420)      *P* value           VAS health (N = 416)   *P* value           VAS fatigue (N = 416)   *P* value
  ------------------------------------------------------------ ----------------------------- ------------------- ------------------- ---------------------- ------------------- ----------------------- -----------
  Gender                                                       Male                          0.78 (0.73--0.82)   0.022               60.9 (56.7--65.1)      0.512               50.1 (42.1--58.2)       0.059

                                                               Female                        0.74 (0.69--0.78)                       59.6 (55.8--63.5)                          55.0 (47.5--62.6)       

  Age                                                          18--49                        0.74 (0.70--0.79)   0.617               57.8 (53.4--62.2)      0.155               53.4 (45.3--61.6)       0.573

                                                               50--54                        0.74 (0.69--0.80)                       57.7 (53.1--62.3)                          56.2 (47.9--64.6)       

                                                               55--59                        0.78 (0.73--0.83)                       58.6 (53.7--63.4)                          52.5 (43.7--61.3)       

                                                               60--64                        0.76 (0.71--0.82)                       62.9 (57.4--68.5)                          49.8 (40.3--59.3)       

                                                               65--70                        0.75 (0.69--0.81)                       64.3 (58.3--70.4)                          50.9 (41.1--60.7)       

  Place of birth                                               France                        0.75 (0.71--0.79)   0.528               62.8 (59.2--66.3)      0.017               53.9 (46.5--61.4)       0.350

                                                               Abroad                        0.76 (0.71--0.81)                       57.8 (53.2--62.4)                          51.2 (42.8--59.6)       

  Education                                                    No bachelor level             0.74 (0.69--0.78)   0.041               59.9 (55.9--63.9)      0.689               53.3 (45.5--61.1)       0.567

                                                               Bachelor level                0.78 (0.73--0.82)                       60.7 (56.6--64.7)                          51.8 (44.0--59.7)       

  Work                                                         Yes                           0.80 (0.75--0.84)   0.001               63.8 (59.5--68.0)      0.001                                       

                                                               No                            0.72 (0.67--0.76)                       56.8 (52.9--60.7)                                                  

  Fibrosis stage                                               F0-F1                                                                 62.7 (58.2--67.1)      0.039                                       

                                                               F2                                                                    56.9 (52.3--61.5)                                                  

                                                               F3-F4                                                                 61.2 (57.0--65.4)                                                  

  Severe comorbidities[^a^](#t003fn001){ref-type="table-fn"}   Yes                           0.72 (0.67--0.77)   \< .0001            57.7 (53.7--61.8)      0.008                                       

  No                                                           0.79 (0.75--0.84)                                 62.8 (58.9--66.7)                                                                      

  Overweight[^b^](#t003fn002){ref-type="table-fn"}             Yes                           0.73 (0.69--0.78)   0.017                                                          55.3 (47.6--63.1)       0.031

                                                               No                            0.78 (0.74--0.82)                                                                  49.8 (41.9--57.7)       

  Psychiatric disorders                                        Yes                                                                   57.0 (51.2--62.7)      0.023               58.3 (48.6--67.9)       0.004

  No                                                                                                             63.6 (60.8--66.4)                          46.9 (40.1--53.7)                           

  Perceived progression of CHC between infection and today     Very comforting               0.84 (0.78--0.90)   \< .0001            71.2 (65.2--77.1)      \< .0001            41.6 (31.4--51.8)       \< .0001

  Rather comforting                                            0.82 (0.77--0.86)                                 64.8 (61.2--68.4)                          50.5 (43.0--58.0)                           

  Rather worrying                                              0.72 (0.67--0.77)                                 54.2 (49.6--58.7)                          61.1 (53.0--69.3)                           

  Very worrying                                                0.66 (0.59--0.73)                                 51.0 (44.4--57.5)                          57.1 (46.6--67.6)                           

  Need to talk with people with CHC                            Very often                                                                                                       57.4 (38.6--76.1)       0.027

  Often                                                                                                                                                     47.2 (37.9--56.6)                           

  Occasionally                                                                                                                                              56.7 (49.7--63.7)                           

  Not at all                                                                                                                                                49.1 (42.9--55.3)                           

  Entourage\                                                   Yes, they are uncomfortable                                           57.1 (51.8--62.3)      0.003               59.5 (50.4--68.7)       0.001
  uncomfortable since their knowledge of CHC                                                                                                                                                            

  Noone is uncomfortable                                                                                         64.7 (61.0--68.3)                          46.7 (39.2--54.1)                           

  No, because nobody knows                                                                                       59.1 (54.2--64.0)                          51.5 (42.6--60.4)                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Diabetes, non-liver related transplant, psychiatric disorders, drug addiction / alcohol

^b^BMI\>25 kg/m^2^

Regarding VAS for health and fatigue, similar results were found, except that VAS deteriorated significantly in the presence of psychiatric disorders and for patients feeling that their entourage felt uncomfortable since finding out about their CHC status. Moreover, general health was significantly lower for patients in F2 (56.9) compared to those in F0-F1 (62.7) and F3-F4 (61.2).

Discussion {#sec014}
==========

This is the first study conducted in France to assess QoL in a large sample of patients affected by CHC. We found that EQ-5D utility values, as well as overall health and fatigue assessed by VAS, were mainly influenced by socio-demographic characteristics (unemployment), by comorbidities (including overweight), and by individual perceptions about CHC progression, rather than by the clinical characteristics of CHC (fibrosis stage, genotype, treatment-naïve status).

Although the stage of fibrosis significantly affects EQ-5D in univariate analysis, it was not found to be an independent factor of HRQoL. Similarly, Hsu *et al* \[[@pone.0215596.ref017],[@pone.0215596.ref018]\] did not find an association between HRQoL and the stage of fibrosis, and emphasized the greater impact of socio-demographic variables on HRQoL.

It was not surprising to find that unemployment, overweight, psychiatric disorders, and comorbidities decrease HRQoL. Unemployment was also found to be significantly associated with decreased HRQoL by Pol *et al* \[[@pone.0215596.ref013]\]. Multiple studies found an association between each of those comorbidities and decreased HRQoL \[[@pone.0215596.ref026]--[@pone.0215596.ref028]\]. In our study, over a third of patients reported comorbidities such as diabetes, arterial hypertension, chronic kidney disease, or hemophilia. During the interview, patients reporting comorbidities were systematically asked to directly compare the severity of CHC with that of other comorbidities (N = 222). Forty-four percent felt that CHC was more severe than their other comorbidities, 36% felt CHC was as severe, but 20% felt CHC was less severe than other comorbidities (not shown). These results suggest that the eradication of HCV after treatment will not necessarily improve the HRQoL of those patients with comorbidities and emphasize a need for active therapeutic interventions regarding these comorbidities.

Patients perception on CHC disease was found to be associated with HRQoL. This perception was principally related to the stage of fibrosis. Patients who saw their disease progress to F3-F4 at the moment of this study were obviously more worried than those at F0-F2. However, despite minimal fibrosis, F0-F1 patients were also found to be worried (17% seeing CHC disease as rather or very worrying). Indeed, as stated by others, HRQoL also decreases along with patients\' anxiety regarding the evolution of their disease \[[@pone.0215596.ref029]\] which may be unrelated to fibrosis stage. For example, we found that HRQoL was also impacted by the feeling of the entourage. In a large proportion of patients, the entourage was unware of the CHC status or, when knowing it, felt uncomfortable. In these cases, these feelings may contribute to a sense of isolation on the part of the patient; again regardless to the fibrosis stage.

Our study has some limitations. First, it was conducted in only three reference centers. These were deliberately chosen to yield a geographically comprehensive representation of patients in France. Despite this limitation, patients' characteristics were representative of CHC patients in France, with a majority of men, an average age of around 54, and two-thirds of patients with genotype 1 \[[@pone.0215596.ref030]\]. Second, we used the EQ-5D instrument to assess the self-reported HRQoL of patients because it is a commonly used generic measure of health that is recommended for analyzing cost-effectiveness \[[@pone.0215596.ref031],[@pone.0215596.ref032]\]. However, it was reported not to be very sensitive to variations in HRQoL \[[@pone.0215596.ref032]--[@pone.0215596.ref033]\]. Therefore we added more sensitive measurement instruments with two visual analogue scales on overall health and fatigue. As in previous studies, the main results based on EQ-5D utility were similar to those obtained with the more sensitive VAS scores. Finally, our study took place over the year 2014; one may consider that the patients knowledge of new DAA at that time where less than today. Thus, a study conducted today may in particular result into patients with higher quality of lives.

In conclusion, factors such as the perceived progression of CHC, the need among patients to share the experience of their disease by talking with other CHC sufferers, and a patient\'s entourage being uncomfortable in the knowledge of their CHC diagnosis, significantly impact HRQoL, but not the fibrosis stage. These variables should be considered when providing care to HCV patients and deciding which subgroup of patients should be treated. The presence of comorbidities, frequent in patients with HCV disease, was also associated with HRQoL. This may imply that the eradication of HCV does not necessarily improve the HRQoL of patients who continue to live with other diseases.

We would like to thank everyone who helped us to include and follow patients in Lille, Paris and Montpellier centers.
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